Physician profile
Lisa Ann Sharp
NPI 1275524258
$1,221.91
in general payments reported to CMS, 2019-2025
26 companies · $147 in 2025
The $147 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $11.94 · 2022: $257 · 2023: $345 · 2024: $461 · 2025: $147.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $953.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $953.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $358.28 | 2023-2025 | Qelbree, Qelbree |
| Sanofi Pasteur INC. | $169.62 | 2022-2024 | |
| Corium, LLC | $82.29 | 2023-2024 | Azstarys |
| Astrazeneca Pharmaceuticals LP | $63.26 | 2023 | Flumist Quadrivalent |
| Collegium Pharmaceutical, INC. | $58.04 | 2025 | Jornay Pm |
| Sanofi-Aventis U.S. LLC | $52.91 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $47.04 | 2022-2024 | Gardasil 9, M-M-R II, Vaxneuvance |
| Tris Pharma INC | $46.69 | 2021-2024 | Dyanavel Xr |
| Bayer Healthcare Pharmaceuticals INC. | $39.31 | 2023 | |
| Neurelis, INC. | $29.26 | 2022-2023 | Valtoco |
| Nestle Healthcare Nutrition INC. | $23.27 | 2022 | |
| Janssen Pharmaceuticals, INC | $23.03 | 2024 | Spravato |
| Kaleo, INC. | $21.87 | 2023 | Auvi-Q |
| Cranial Technologies, INC | $19.69 | 2023 | Doc Band |
| Sobi, INC | $18.87 | 2023 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $18.76 | 2023 | |
| Verrica Pharmaceuticals INC. | $17.13 | 2024 | Ycanth |
| Daiichi Sankyo INC. | $16.74 | 2023 | Injectafer |
| Astellas Pharma US INC | $16.15 | 2023 | Veozah |
| Organon LLC | $15.25 | 2023 | Nexplanon |
| Ironshore Pharmaceuticals INC. | $15.13 | 2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.04 | 2022 | |
| Amgen INC. | $14.11 | 2023 | Repatha, Otezla |
| Abbvie INC. | $13.68 | 2022 | |
| Phathom Pharmaceuticals, INC. | $13.57 | 2023 | Voquezna |
| Lucid Diagnostics INC. | $12.92 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Sharp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.